Merck & Co., Inc. (MRK)
After hours:
| Previous Close | 118.59 |
| Open | 119.10 |
| Bid | 117.85 x 1100 |
| Ask | 117.89 x 800 |
| Day's Range | 117.66 - 120.30 |
| 52 Week Range | 99.14 - 134.63 |
| Volume | |
| Avg. Volume | 9,593,922 |
| Market Cap | 298.702B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 21.82 |
| EPS (TTM) | 5.40 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | 3.08 (2.61%) |
| Ex-Dividend Date | Sept 16, 2024 |
| 1y Target Est | 140.15 |
Business WireIfinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J., September 07, 2024--Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial showed ifinatamab deruxtecan (I-DXd) continues to demonstrate promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These data were featured today as part of a press conference and will be presented during an oral presentation (OA04.03) on Sunday at the 2024 World Conference on
Simply Wall St.Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
CNW GroupMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WELIREG® (belzutifan) on August 30th. The pCPA negotiates on behalf of the provinces, territories, and federal drug programs, serving as a critical step in bringing WELIREG® closer to public reimbursement.
